Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7204239 plus risdiplam in ambulant pediatric spinal muscular atrophy
2021-003417-19Phase 2Active
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal muscular atrophy (SMA) and Spinal muscular atrophy type 3 (SMA3) comparing RO7204239 + risdiplam with Placebo + risdiplam (2 arms). Primary endpoint: Primary endpoints Part 1. Started Oct 2021; status: active.
02
Drugs
emugrobartrisdiplam
03
Conditions
spinal muscular atrophy (SMA)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on 2021-003417-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003417-19.